Geron (NASDAQ:GERN) Downgraded by HC Wainwright to Neutral

HC Wainwright cut shares of Geron (NASDAQ:GERN) from a buy rating to a neutral rating in a report issued on Wednesday morning, Marketbeat Ratings reports.

GERN has been the topic of several other reports. Needham & Company LLC raised their target price on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 13th. B. Riley lowered their price target on Geron from $5.50 to $3.50 and set a “buy” rating on the stock in a report on Tuesday, February 18th. Finally, Barclays upgraded shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Geron has an average rating of “Moderate Buy” and a consensus target price of $6.91.

Geron Stock Performance

Shares of GERN opened at $1.61 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. Geron has a 12-month low of $1.46 and a 12-month high of $5.34. The business’s fifty day moving average price is $3.00 and its 200 day moving average price is $3.81. The stock has a market capitalization of $973.25 million, a PE ratio of -5.03 and a beta of 0.53.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). The company had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. Equities research analysts forecast that Geron will post -0.25 EPS for the current year.

Institutional Investors Weigh In On Geron

Several large investors have recently made changes to their positions in the company. Alternative Investment Advisors LLC. boosted its stake in Geron by 13.3% in the third quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 2,612 shares in the last quarter. Rovin Capital UT ADV raised its holdings in shares of Geron by 26.9% in the fourth quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 3,660 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Geron by 23.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 4,094 shares in the last quarter. Xponance Inc. grew its holdings in Geron by 12.9% during the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 4,829 shares during the last quarter. Finally, US Bancorp DE increased its position in Geron by 68.4% in the 3rd quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 7,429 shares in the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.